Topiramate (All indications) updated on 04-22-2025

Neonatal medical care

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18704
R79576		 Mazzone (Topiramate) (Controls exposed to LTG) (Mixed indications), 2025 Neonatal intensive care unit admission during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.83 [0.56;1.22] C
excluded (control group) 		34/391   152/1,469 186 391
ref
S18705
R79583		 Mazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 Neonatal intensive care unit admission during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.02 [0.65;1.62] 34/391   44,768/624,794 44,802 391
ref
S8602
R28638		 Bank (Topiramate) (Mixed indications) , 2017 Admission to neonatal intensive care unit (NICU) or Special Care Nursery during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 5.00 [0.27;91.52] C 1/2   6/36 7 2
ref
Total 2 studies 1.15 [0.51;2.62] 44,809 393
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Mazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025Mazzone, 2025 1 1.02[0.65; 1.62]44,80239192%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Bank (Topiramate) (Mixed indications) , 2017Bank, 2017 2 5.00[0.27; 91.52]728%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 11% 1.15[0.51; 2.62]44,8093930.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Controls unexposed, NOS) (Mixed indications; 2: Topiramate) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.15[0.51; 2.62]44,80939311%NAMazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 Bank (Topiramate) (Mixed indications) , 2017 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.02[0.65; 1.61]44,802391 -NAMazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 1 exposed to other treatment, sickexposed to other treatment, sick 5.00[0.27; 91.52]72 -NABank (Topiramate) (Mixed indications) , 2017 1 Tags Adjustment   - No  - No 5.00[0.27; 91.52]72 -NABank (Topiramate) (Mixed indications) , 2017 1   - Yes  - Yes 1.02[0.65; 1.61]44,802391 -NAMazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 1 All studiesAll studies 1.15[0.51; 2.62]44,80939311%NAMazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 Bank (Topiramate) (Mixed indications) , 2017 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 18704

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.02[0.65; 1.61]44,802391 -NAMazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.12[0.30; 4.16]19339331%NAMazzone (Topiramate) (Controls exposed to LTG) (Mixed indications), 2025 Bank (Topiramate) (Mixed indications) , 2017 20.510.01.0